Breast Cancer

Breast cancer is the most common cancer affecting women worldwide, with approximately 2.3 million new cases diagnosed each year. The disease develops when cells in breast tissue acquire genetic mutations that cause them to grow and divide uncontrollably, forming tumors that can invade surrounding tissue and spread to other parts of the body. Breast cancer isn't a single disease - it's actually multiple distinct types classified by the proteins and receptors found on cancer cells. The most common types are hormone receptor-positive (where cancer cells respond to estrogen or progesterone), HER2-positive (where cells have extra copies of a growth-promoting protein), and triple-negative (lacking these three receptors). These biological differences fundamentally affect how cancers behave and which treatments work. Most breast cancers begin in the milk ducts or milk-producing glands, though they can start in other breast tissues. Risk factors include age, family history, certain genetic mutations (like BRCA1/BRCA2), reproductive history, hormone exposure, lifestyle factors, and previous radiation exposure. Many people have no identifiable risk factors, and most breast lumps discovered are benign (non-cancerous), making screening and diagnostic accuracy important.

Treatment is highly personalized based on cancer type, stage, and molecular features. Surgery remains central - either lumpectomy (removing the tumor while preserving the breast) or mastectomy (removing the breast), often combined with lymph node evaluation. Radiation therapy typically follows lumpectomy and sometimes mastectomy to eliminate remaining cancer cells. For hormone receptor-positive cancers (about 70% of cases), hormone-blocking therapies like tamoxifen or aromatase inhibitors are standard, often taken for 5-10 years to prevent recurrence. HER2-positive cancers are treated with targeted antibodies like trastuzumab (Herceptin) and pertuzumab, which have transformed outcomes for this subtype. Chemotherapy is used based on cancer characteristics and recurrence risk, with genomic tests now helping determine who truly needs it versus who can safely avoid it. CDK4/6 inhibitors combined with hormone therapy have become standard for advanced hormone-positive disease, significantly extending survival. Immunotherapy with checkpoint inhibitors is now approved for certain triple-negative breast cancers. Newer surgical techniques offer better cosmetic outcomes, and supportive medications effectively manage treatment side effects. For early-stage disease, cure rates are high - over 90% of people diagnosed with localized breast cancer are alive five years later.

Triple-negative breast cancer remains the most challenging subtype to treat because it lacks the targets that make other breast cancers responsive to hormone therapy or HER2-targeted drugs, and only a subset responds to currently available immunotherapy. Metastatic breast cancer - when disease has spread beyond the breast and nearby lymph nodes - is treatable but not curable with current approaches, and better therapies to extend life while maintaining quality of life are needed. Treatment resistance develops over time as cancers acquire new mutations, particularly in metastatic disease where initial therapies eventually stop working. Chemotherapy side effects including neuropathy (nerve damage), fatigue, and cognitive changes affect quality of life, creating need for equally effective but better-tolerated options. Young women diagnosed with breast cancer face unique challenges around fertility preservation, treatment timing, and long-term effects of therapies taken for years during prime working and family-building years. Some people experience long-term side effects from treatments including lymphedema (arm swelling), joint pain from hormone therapies, and heart problems from certain chemotherapies. Predicting which early-stage cancers will recur years or decades later remains imperfect, making it difficult to know who needs more intensive initial treatment versus ongoing surveillance.

Antibody-drug conjugates (ADCs) - targeted antibodies carrying chemotherapy directly to cancer cells - are showing remarkable results in advanced trials, with several new agents targeting HER2-low cancers (a previously difficult-to-treat category) and other markers. Sacituzumab govitecan, an ADC approved for triple-negative and hormone-positive breast cancer, is being tested in earlier disease stages. Next-generation CDK4/6 inhibitors and combinations with other targeted drugs are in Phase 3 trials for hormone-positive cancers. For triple-negative disease, new immunotherapy combinations and agents targeting specific vulnerabilities like PARP inhibitors for BRCA-mutated cancers are advancing. Oral selective estrogen receptor degraders (SERDs) are being tested as more convenient alternatives to injectable formulations. Bispecific antibodies that simultaneously bind cancer cells and immune cells are in trials, designed to force immune system engagement with tumors. Novel HER2-targeted therapies including tucatinib and new ADC formulations are being evaluated in various combinations. Personalized cancer vaccines targeting each patient's specific tumor mutations have shown early promise and are entering larger trials. Researchers are testing whether shorter, less intensive chemotherapy regimens guided by mid-treatment response assessment can achieve similar results with fewer side effects.

CAR-T cell therapy, which has transformed blood cancer treatment, is being adapted for solid tumors including breast cancer, with researchers engineering immune cells to recognize breast cancer markers and overcome the challenges of reaching and penetrating solid tumor masses. Scientists are developing next-generation immunotherapies including cancer vaccines, engineered bacteria that colonize tumors and stimulate immune responses, and novel checkpoint inhibitors targeting newly discovered immune pathways. Precision medicine approaches use artificial intelligence to analyze genetic, molecular, and clinical data to predict which treatments will work for individual patients before starting therapy. Researchers are investigating drugs that target cancer stem cells - the small population of cells thought responsible for recurrence and metastasis. Liquid biopsies detecting tumor DNA fragments in blood are being refined to catch recurrence earlier than imaging, monitor treatment response in real-time, and potentially screen high-risk individuals. Scientists are exploring the tumor microenvironment - the blood vessels, immune cells, and supportive tissue surrounding cancer - to find new drug targets. Nanotechnology approaches are being developed to improve drug delivery, concentrating chemotherapy at tumor sites while sparing healthy tissue. Researchers are investigating whether the gut microbiome influences treatment response and whether modifying intestinal bacteria could improve outcomes. Organoid technology - growing miniature patient tumors in the laboratory enables testing multiple treatments to identify the best option before starting therapy. Metabolic therapies targeting how cancer cells produce energy and drugs that prevent cancer cells from repairing DNA damage are in development.